Contact Information: INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Janice Meraglia 631-444-6293 fax: 631-444-8848 FCMN Contact: Web site: http://www.ADNAS.com
Applied DNA Sciences Adds Director of Communications in Response to Growth Demands
| Source: Applied DNA Sciences
STONY BROOK, NY--(Marketwire - February 26, 2009) - Applied DNA Sciences, Inc. (OTCBB : APDN ), a
provider of DNA-based security solutions, today announced that Janice
Meraglia has assumed the new role of Director of Communications,
encompassing a broad range of issues including Investor and Public
Relations. Ms. Meraglia will also help Applied DNA continue its progress
in Government Contracts and the Financial Applications verticals.
APDN offers platform technologies that are relevant to both state and
federal governments, and include the following applications: authentication
of passports, licenses and identification, authentication of currency,
homeland security applications, trade regulations and compliance with
federal labeling laws. Our patented DNA technologies can protect the
financial industry by: securing currency during transport, authenticating
financial documents, and tracing the DNA native to the unique papers used
in finance. Applied DNA has prevalidated these applications; Ms. Meraglia
will manage sales in both areas.
For over 20 years, Ms. Meraglia has successfully partnered with other
leaders in start-up and entrepreneurial ventures, as well as launching new
businesses within large financial institutions. She is a senior executive
with a proven track record in the development, implementation and
management of global administrative infrastructures.
Most recently, Ms. Meraglia was Senior Vice President and Chief
Administrative Officer of the Global Credit Products businesses at Lehman
Brothers NYC headquarters. There she worked with functional and regional
managers across four credit businesses to develop and deliver strategic
goals. Prior to this position, Ms. Meraglia held a similar role at CIBC
World Markets where she was one of the founding partners of the Canadian
Bank's new financial services based in New York.
"It feels great to be passionate again about a business prospect that will
have a global impact. I believe the opportunity to provide commercial
forensic solutions, in a world economy that is losing money to illegitimate
trade, is very compelling," said Ms. Meraglia. "We provide an invaluable
tool that can be used to authenticate products and help save lives. I am
very excited to work with the world class team at Applied DNA."
Ms. Meraglia received a Bachelor of Science degree in Finance from St.
John's University. She is actively involved with various philanthropic
organizations in capacities ranging from sponsorship to fundraising. Ms.
Meraglia is also a two-year recipient of the President's Corporate
Citizenship Award from Lehman Brothers.
About APDN
Applied DNA Sciences markets and sells DNA security solutions to protect
products, brands, and intellectual property from counterfeiting and
diversion. Its patented technologies, sold under SigNature® DNA use DNA
from plants to mark and authenticate products in a unique manner that
essentially can not be copied. Applied DNA also provides BioMaterial
GenoTyping™ services by using genomic DNA present in natural materials
to identify the original source of DNA present in finished products. Both
platform technologies protect brands and products in a wide range of
industries and provide a forensic chain of evidence to enable enforcement
agencies to prosecute perpetrators. To learn more, go to www.adnas.com.
APDN's common stock is listed on the Over-The-Counter Bulletin Board under
the symbol "APDN."
The statements made by APDN may be forward-looking in nature and are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements describe APDN's future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of which
are beyond the control of APDN. Actual results could differ materially from
those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN's SEC reports and filings,
including our Annual Report on Form 10-K, filed on December 16, 2008 and
our subsequent quarterly reports on Form 10-Q. APDN undertakes no
obligation to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to reflect the
occurrence of unanticipated events.